Cardiff Oncology Inc Stock Price, News & Analysis

Cardiff Oncology (CRDF) announced plans for a randomized Phase 2 trial, ONSEMBLE, to evaluate onvansertib's efficacy in second-line RAS-mutated metastatic colorectal cancer (mCRC), with topline data expected in 2H 2024. The ongoing Phase 1b/2 trial shows a median duration of response of 11.7 months. Initial results in a Phase 2 trial for pancreatic cancer indicate promising responses. The company's cash resources are projected to cover operations into 2025, emphasizing a strategic focus on mCRC and pancreatic cancer while discontinuing prostate cancer activities.

Cardiff Oncology (Nasdaq: CRDF) announced promising results from its Phase 1b/2 clinical trial of onvansertib combined with FOLFIRI/bevacizumab for second-line treatment of KRAS-mutated metastatic colorectal cancer (mCRC). The trial demonstrated a median duration of response (mDoR) of 11.7 months and an overall response rate (ORR) of 35%, surpassing historical benchmarks. Additionally, patients with a ≥90% decrease in KRAS mutant allele frequency showed significantly better outcomes. These findings suggest onvansertib may address critical treatment gaps in mCRC, with further data presented at ESMO Congress 2022.

Cardiff Oncology, Inc. (Nasdaq: CRDF) will participate in the Baird Global Healthcare Conference and the H.C. Wainwright 24^th Annual Global Investment Conference in New York, NY. The Baird Conference is on September 13, 2022, featuring a fireside chat at 2:00 PM ET. The H.C. Wainwright Conference is on September 14, 2022, with a corporate presentation at the same time. The company focuses on developing novel therapies for various cancers, leveraging PLK1 inhibition through their lead asset, onvansertib. More details are available on their official website.

Cardiff Oncology, Inc. (Nasdaq: CRDF) announced the acceptance of two abstracts for poster presentations at the European Society for Medical Oncology (ESMO) Congress 2022, scheduled for September 9-13 in Paris. The presentations focus on the efficacy of onvansertib, a PLK1 inhibitor, in overcoming irinotecan resistance in KRAS-mutated metastatic colorectal cancer. The data suggest early decreases in KRAS mutant allele frequency (MAF) may predict patient response. A conference call on September 12 will discuss clinical updates and development pathways for onvansertib.

Cardiff Oncology, Inc. (Nasdaq: CRDF) will host a webcast and conference call on September 12, 2022, at 4:30 PM ET, to discuss the development pathway for onvansertib in KRAS-mutated metastatic colorectal cancer, alongside updates on other programs. The event will include ongoing clinical trial data updates. In addition, Cardiff management will attend the Baird Global Healthcare Conference on September 13 and the H.C. Wainwright Global Investment Conference on September 14. Details of the call can be found on their website.

Cardiff Oncology, Inc. (Nasdaq: CRDF) announced significant progress in cancer therapies, presenting promising preclinical data at AACR. Notably, onvansertib combined with olaparib showed a statistically significant survival benefit in ovarian cancer models. In metastatic castration-resistant prostate cancer (mCRPC), updated clinical results indicated increasing disease control rates with higher onvansertib doses, reaching 75% in the most intense treatment group. As of June 30, 2022, the company reported $122 million in cash, with an increase in operating expenses driven by R&D efforts and staff expansion.

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology firm, will participate in the William Blair Biotech Focus Conference 2022 on July 12-13, 2022, held at The St. Regis New York. The company aims to leverage its expertise in PLK1 inhibition to develop novel cancer therapies, particularly focusing on its lead asset, onvansertib, which targets treatment-resistant cancers. A pre-recorded fireside chat will be available on-demand starting July 11, 2022. For more details, visit Cardiff Oncology's website.

Cardiff Oncology, Inc. (Nasdaq: CRDF), a biotechnology firm specializing in PLK1 inhibition for cancer therapies, will engage in a fireside chat and one-on-one meetings at the H.C. Wainwright Global Investment Conference in Miami, Florida, from May 23-26, 2022. The fireside chat is scheduled for May 24, 2022, at 5:00 PM ET. The event is a platform for the company to discuss its innovative therapies, particularly its lead asset, onvansertib, aimed at overcoming treatment resistance in various cancers. A replay will be available on their website following the event.

Cardiff Oncology (Nasdaq: CRDF) reported promising Phase 1b/2 results for its lead KRAS-mutated metastatic colorectal cancer program, showcasing an objective response rate (ORR) of 34% compared to historical controls of 5-13%. Additionally, Phase 2 data from its metastatic castration-resistant prostate cancer trial indicated that 75% of patients on the highest dose achieved disease control. The company holds approximately $129.4 million in cash as of March 31, 2022, with increased operating expenses attributed to development efforts for onvansertib. These results position Cardiff for future growth and advancement in oncology.